Table 2.
Clinical presentations of 103 cases of GBS invasive diseases categorized based on the length of the CRISPR-RFLP array and eBURST analysis.
| Group | A | B | C |
|---|---|---|---|
| Case number, n (% of total) | 22 (21.4) | 34 (33.0) | 47 (45.6) |
| RFLP patterns | |||
| <1000 bp | 15 (68.2) | 2 (5.9) | 4 (8.5) |
| 1000–1300 bp | 3 (13.6) | 32 (94.1) | 42 (89.4) |
| >1300 bp | 4 (18.2) | 0 (0) | 1 (2.1) |
| Birth body weight (g) | 2914.8 ± 430.2 | 2880.0 ± 644.5 | 3002.6 ± 683.0 |
| Gestational age (weeks) | 38.5 ± 1.8 | 37.6 ± 3.1 | 38.0 ± 3.1 |
| Prematurity | 3 (13.6) | 8 (23.5) | 8 (17.0) |
| Sex (male/female) | 7 (31.8)/15 (68.2) | 24 (70.6)/10 (29.4) | 18 (38.3)/29 (61.7) |
| Any chronic comorbidity | 1 (4.5) | 3 (8.8) | 5 (10.6) |
| Antibiotic susceptibility | |||
| Erythromycin (R) | 17 (77.3) | 2 (82.4) | 47 (100.0) |
| Clindamycin (R) | 15 (68.2) | 2 (70.6) | 47 (100.0) |
| Clinical presentations | |||
| Severe sepsis * | 14 (63.6) ** | 7 (20.6) | 18 (38.3) |
| Meningitis | 11 (50.0) ** | 6 (17.6) | 12 (25.5) |
| Neurological sequelae | 6 (27.3) | 4 (11.8) | 6 (12.8) |
| Final mortality | 1 (4.5) | 1 (0) | 2 (4.3) |
All data are presented as number (%); R: resistance; RFLP: restriction fragment length polymorphism; * Severe sepsis is defined as the presence of septic shock, respiratory failure requiring intubation, and/or multiple organ failure; ** p < 0.05.